Virtual bees and wasps may alter allergy immune responses — a trial puts it to the test

NCT ID NCT07721233

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests whether immersive virtual reality (VR) exposure to bees or wasps can influence immune, brain, and body responses in adults with venom allergy. Participants will experience a realistic VR picnic scene where virtual insects approach and simulate a sting, while researchers measure changes in blood markers, heart rate, brain activity, and more. The goal is to better understand how the brain and immune system interact in allergy, and whether VR could one day support conventional allergy treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
immersive virtual reality exposure to allergen-related stimuli
What this could lead to
If it works, this could point toward a new way to complement allergy treatments using virtual reality.
What could go wrong
This is an early exploratory study. It does not involve real insect exposure, so any immune changes seen may not translate to real-world allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 81 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age 18 years or older. * Able to understand the participant information and provide written informed consent. * Willing and able to comply with all study procedures. Part 1 - Healthy volunteers * No known bee or wasp venom allergy. * No current allergen immunotherapy or monoclonal antibody treatment. * No known active allergic, autoimmune, inflammatory, or immunodeficiency disorder requiring systemic treatment. Part 1 - Participants with bee or wasp venom allergy * Documented bee and/or wasp venom allergy based on medical history and/or routine allergy work-up. * No ongoing venom immunotherapy at the time of inclusion in Part 1. * No current monoclonal antibody treatment or systemic immunosuppressive treatment at the time of testing. Part 2 - Participants undergoing venom immunotherapy * Documented bee and/or wasp venom allergy based on medical history and/or routine allergy work-up. * Planned initiation of or ongoing treatment with standard-of-care venom immunotherapy. Exclusion Criteria * Absence of written informed consent. * Inability to understand the study information or provide informed consent. * Age younger than 18 years. * Current systemic immunosuppressive therapy. * Current monoclonal antibody treatment for an allergic, autoimmune, or inflammatory disease at the time of testing. * Ongoing allergen immunotherapy for allergies other than bee or wasp venom allergy. * Leukocyte count below 3.5 G/L. * Hemoglobin below approximately 120 g/L in women or below approximately 130 g/L in men. * Bee or wasp sting reaction within the previous 2 months. * Intolerance to virtual reality, as assessed during a preliminary interview

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hymenoptera venom allergy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.